FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4327898720> ?p ?o ?g. }

• W4327898720 endingPage "1237" @default.
• W4327898720 startingPage "1227" @default.
• W4327898720 abstract "To evaluate the safety and immunogenicity of V114 (15-valent pneumococcal conjugate vaccine [PCV] containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9 V, 14, 18C, 19A, 19F, 22F, 23F, 33F), followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) 8 weeks later, in children living with HIV.This phase 3 study (NCT03921424) randomized participants 6-17 years of age with HIV (CD4+ T-cell count ≥200 cells/μl, plasma HIV RNA < 50 000 copies/ml) to receive V114 or 13-valent PCV (PCV13) in a double-blind manner on Day 1, followed by PPSV23 at Week 8.Adverse events (AEs) and pneumococcal serotype-specific immunoglobulin G (IgG) and opsonophagocytic activity (OPA) were evaluated 30 days after each vaccination.Proportions of participants experiencing at least one AE post-PCV were 78.8% in the V114 group (n = 203) and 69.6% in the PCV13 group (n = 204); respective proportions post-PPSV23 were 75.4% (n = 203) and 77.2% (n = 202). There were no vaccine-related serious AEs. IgG geometric mean concentrations (GMCs) and OPA geometric mean titers (GMTs) were generally comparable between V114 and PCV13 for shared serotypes at Day 30 and were higher for V114 compared with PCV13 for the additional V114 serotypes 22F and 33F. Approximately 30 days after PPSV23, IgG GMCs and OPA GMTs were generally comparable between the V114 and PCV13 groups for all 15 serotypes in V114.In children living with HIV, a sequential administration of V114 followed 8 weeks later with PPSV23 is well tolerated and induces immune responses for all 15 pneumococcal serotypes included in V114." @default.
• W4327898720 created "2023-03-21" @default.
• W4327898720 creator A5000268660 @default.
• W4327898720 creator A5005175939 @default.
• W4327898720 creator A5008142233 @default.
• W4327898720 creator A5009294471 @default.
• W4327898720 creator A5029916608 @default.
• W4327898720 creator A5030667842 @default.
• W4327898720 creator A5032466814 @default.
• W4327898720 creator A5039855616 @default.
• W4327898720 creator A5042453482 @default.
• W4327898720 creator A5050857666 @default.
• W4327898720 creator A5063570763 @default.
• W4327898720 creator A5071188493 @default.
• W4327898720 creator A5077502906 @default.
• W4327898720 creator A5078158945 @default.
• W4327898720 creator A5086250528 @default.
• W4327898720 creator A5089484814 @default.
• W4327898720 creator A5091397473 @default.
• W4327898720 date "2023-03-17" @default.
• W4327898720 modified "2023-10-14" @default.
• W4327898720 title "A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV" @default.
• W4327898720 cites W1963985157 @default.
• W4327898720 cites W1993377959 @default.
• W4327898720 cites W2006694705 @default.
• W4327898720 cites W2011842943 @default.
• W4327898720 cites W2012174372 @default.
• W4327898720 cites W2014361456 @default.
• W4327898720 cites W2072177880 @default.
• W4327898720 cites W2098698934 @default.
• W4327898720 cites W2107045752 @default.
• W4327898720 cites W2112765785 @default.
• W4327898720 cites W2137591261 @default.
• W4327898720 cites W2149563075 @default.
• W4327898720 cites W2265539675 @default.
• W4327898720 cites W2613751645 @default.
• W4327898720 cites W2810131685 @default.
• W4327898720 cites W2810449130 @default.
• W4327898720 cites W2950614621 @default.
• W4327898720 cites W2974439873 @default.
• W4327898720 cites W3043620968 @default.
• W4327898720 cites W3088047542 @default.
• W4327898720 cites W3107861020 @default.
• W4327898720 cites W3196769760 @default.
• W4327898720 cites W3197128884 @default.
• W4327898720 cites W3213811737 @default.
• W4327898720 cites W4200373004 @default.
• W4327898720 cites W4296514321 @default.
• W4327898720 doi "https://doi.org/10.1097/qad.0000000000003551" @default.
• W4327898720 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36939067" @default.
• W4327898720 hasPublicationYear "2023" @default.
• W4327898720 type Work @default.
• W4327898720 citedByCount "1" @default.
• W4327898720 countsByYear W43278987202023 @default.
• W4327898720 crossrefType "journal-article" @default.
• W4327898720 hasAuthorship W4327898720A5000268660 @default.
• W4327898720 hasAuthorship W4327898720A5005175939 @default.
• W4327898720 hasAuthorship W4327898720A5008142233 @default.
• W4327898720 hasAuthorship W4327898720A5009294471 @default.
• W4327898720 hasAuthorship W4327898720A5029916608 @default.
• W4327898720 hasAuthorship W4327898720A5030667842 @default.
• W4327898720 hasAuthorship W4327898720A5032466814 @default.
• W4327898720 hasAuthorship W4327898720A5039855616 @default.
• W4327898720 hasAuthorship W4327898720A5042453482 @default.
• W4327898720 hasAuthorship W4327898720A5050857666 @default.
• W4327898720 hasAuthorship W4327898720A5063570763 @default.
• W4327898720 hasAuthorship W4327898720A5071188493 @default.
• W4327898720 hasAuthorship W4327898720A5077502906 @default.
• W4327898720 hasAuthorship W4327898720A5078158945 @default.
• W4327898720 hasAuthorship W4327898720A5086250528 @default.
• W4327898720 hasAuthorship W4327898720A5089484814 @default.
• W4327898720 hasAuthorship W4327898720A5091397473 @default.
• W4327898720 hasBestOaLocation W43278987201 @default.
• W4327898720 hasConcept C10389963 @default.
• W4327898720 hasConcept C159047783 @default.
• W4327898720 hasConcept C159654299 @default.
• W4327898720 hasConcept C203014093 @default.
• W4327898720 hasConcept C22070199 @default.
• W4327898720 hasConcept C2778866548 @default.
• W4327898720 hasConcept C2779301066 @default.
• W4327898720 hasConcept C2779664119 @default.
• W4327898720 hasConcept C2780868878 @default.
• W4327898720 hasConcept C2781253189 @default.
• W4327898720 hasConcept C3020803494 @default.
• W4327898720 hasConcept C501593827 @default.
• W4327898720 hasConcept C71924100 @default.
• W4327898720 hasConcept C86803240 @default.
• W4327898720 hasConcept C89423630 @default.
• W4327898720 hasConceptScore W4327898720C10389963 @default.
• W4327898720 hasConceptScore W4327898720C159047783 @default.
• W4327898720 hasConceptScore W4327898720C159654299 @default.
• W4327898720 hasConceptScore W4327898720C203014093 @default.
• W4327898720 hasConceptScore W4327898720C22070199 @default.
• W4327898720 hasConceptScore W4327898720C2778866548 @default.
• W4327898720 hasConceptScore W4327898720C2779301066 @default.
• W4327898720 hasConceptScore W4327898720C2779664119 @default.
• W4327898720 hasConceptScore W4327898720C2780868878 @default.
• W4327898720 hasConceptScore W4327898720C2781253189 @default.

• next